분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-08-29 02:53:15 , Hit : 2135
 Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU


Megan Brooks
DisclosuresAugust 27, 2014


Editors' Recommendations
EU Panel Endorses Daclatasvir (Daklinza) for Chronic Hep C
New Hepatitis C Guidelines Are Evolving Documents
HCV Therapy: High Rate of Viral Clearance, No Injections



Receive an email from Medscape whenever new articles on this topic are available.
Personal Alert  Add Hepatitis C to My Topic Alert

Drug & Reference Information
Hepatitis C Test
Chronic Hepatitis C Pathology
Pediatric Hepatitis C

The European Commission has approved daclatasvir (Daklinza, Bristol-Myers Squibb) to treat adults with chronic hepatitis C virus (HCV) infection in combination with other drugs, the company announced today.

The approval follows an endorsement in June by the European Medicines Agency Committee for Medicinal Products for Human Use.

Daclatasvir blocks the action of NS5A, a protein essential for HCV replication. It is indicated for adults infected with HCV genotypes 1, 2, 3, and 4.

In a news release, the company notes that oral daclatasvir in combination with oral sofosbuvir provided cure rates of up to 100% in clinical trials, including in patients with advanced liver disease, genotype 3, and those who have previously failed treatment with protease inhibitors.

Daclatasvir is the first NS5A complex inhibitor approved in the European Union (EU) and, in combination with other drugs, provides a "shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon- and ribavirin-based regimens," the company says.

Across clinical studies, daclatasvir-based regimens have been generally well-tolerated, with low discontinuation rates. The most common adverse effects with daclatasvir when used in combination with other drugs are fatigue, headache, and nausea.

The safety of daclatasvir has been demonstrated in diverse patient populations that include elderly patients, patients with advanced liver disease, post–liver transplant recipients, and patients coinfected with HIV, the company says.

"HCV is a challenging virus to overcome," Michael P. Manns, MD, professor and chairman, Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Germany, said in the release. Daclatasvir, when combined with other compounds, "often results in cure among even the hardest-to-treat patients," he added.

Recommended regimens and treatment durations for daclatasvir-based regimens include:

For HCV genotype 1 or 4 without cirrhosis: daclatasvir plus sofosbuvir for 12 weeks. Consider prolongation to 24 weeks for patients with prior treatment, including a NS3/4A protease inhibitor.


For genotype 1 or 4 with compensated cirrhosis: daclatasvir plus sofosbuvir for 24 weeks. Consider shortening treatment to 12 weeks for previously untreated patients with cirrhosis and positive prognostic factors such as IL28B CC genotype and/or low baseline viral load. Consider adding ribavirin for patients with very advanced liver disease or with other negative prognostic factors, such as prior treatment experience.


For genotype 3 with compensated cirrhosis and/or treatment experienced: daclatasvir plus sofosbuvir plus ribavirin for 24 weeks.


For genotype 4: 24 weeks of daclatasvir plus 24 to 48 weeks of peginterferon alfa and ribavirin. If the patient has HCV RNA undetectable at both treatment weeks 4 and 12, all 3 components of the regimen should be continued for 24 weeks. If the patient achieves undetectable HCV RNA, but not at both treatment weeks 4 and 12, daclatasvir should be discontinued at 24 weeks and peginterferon alfa and ribavirin continued for a total duration of 48 weeks.


Daclatasvir monotherapy is not recommended. The Summary of Product Characteristics will be available online. Commercial availability of daclatasvir in the EU will be determined by individual member states.







1147   CRISPR/Cas9의 대안: CRISPR/Cpf1  이성욱 2015/09/29 1414
1146   CRISPR: No Cutting Required  이성욱 2016/08/06 1638
1145   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 414
1144   CRISPR을 이용하여 마우스의 헌팅톤병 치료 성공  이성욱 2015/10/29 1168
1143   CRISPR의 능력을 배가(倍加)시키는 미니 유전자  이성욱 2015/04/02 1152
1142   CTLA-4 항체의 항암 효과를 높이는 새로운 혼합치료  이성욱 2014/04/21 2104
1141   CU-Boulder researchers uncover new target for cancer research  이성욱 2012/11/06 2704
1140   CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs  이성욱 2015/01/07 1304
1139   C형 간염 바이러스가 간질환을 유발시키는데 필수적인 지방산 합성효소  이성욱 2008/07/14 4845
1138   C형 간염 바이러스의 E2 외피 당단백 구조  이성욱 2013/12/06 2120
1137   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1713
1136   C형 간염, 고지혈증약으로 감염 억제  관리자 2012/01/09 3535
1135   C형 간염에 보다 효과적인 새로운 복합제  이성욱 2015/11/24 978
1134   C형간염 동물모델을 만드는 데 필요한 단백질 발견: 오클루딘(occludin)  이성욱 2009/02/11 5476
1133   C형간염 바이러스의 감염을 차단하는 천연화합물  이성욱 2010/01/08 5235
1132   C형간염 시장 ‘폭발적 성장’ 전망  이성욱 2010/05/25 5410
1131   C형간염 진단 유전자검사 개발  이성욱 2013/03/07 2876
1130   C형간염바이러스의 복제를 돕는 인간의 유전자  이성욱 2009/03/20 5010
1129   C형간염의 자가회복에 영향을 미치는 요인  이성욱 2007/09/04 4812
  Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU  이성욱 2014/08/29 2135

[1][2][3][4][5][6] 7 [8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN